3 Key Takeaways From Keryx's Earnings Report
Keryx , a biotech company that soared in January following positive clinical trial data, released its first-quarter results after the market closed yesterday. Today, shares were down a mere 1.75%.
Earnings reports are often catalysts for stocks, so why were shares basically flat today? What upcoming events should investors keep on their radar? In the following video, health-care analyst Max Macaluso discusses Keryx's results and the main takeaways for investors.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article 3 Key Takeaways From Keryx's Earnings Report originally appeared on Fool.com.Max Macaluso, Ph.D., and The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.